[go: up one dir, main page]

CY1108461T1 - Σφαιρικη κεφαλη του obg3 και χρησεις αυτου για την μειωση της σωματικης μαζας - Google Patents

Σφαιρικη κεφαλη του obg3 και χρησεις αυτου για την μειωση της σωματικης μαζας

Info

Publication number
CY1108461T1
CY1108461T1 CY20081101219T CY081101219T CY1108461T1 CY 1108461 T1 CY1108461 T1 CY 1108461T1 CY 20081101219 T CY20081101219 T CY 20081101219T CY 081101219 T CY081101219 T CY 081101219T CY 1108461 T1 CY1108461 T1 CY 1108461T1
Authority
CY
Cyprus
Prior art keywords
body mass
obg3
obesity
reduce body
brain head
Prior art date
Application number
CY20081101219T
Other languages
English (en)
Inventor
Bernard Bihain
Mary Ruth Erickson
Joachim Fruebis
Original Assignee
Serono Genetics Institute S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Genetics Institute S.A. filed Critical Serono Genetics Institute S.A.
Publication of CY1108461T1 publication Critical patent/CY1108461T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με τον τομέα της έρευνας της παχυσαρκίας. Η παχυσαρκία είναι ένα πρόβλημα της δημόσιας υγείας το οποίο είναι σοβαρό και διαδεδομένο. Έχει αναγνωριστεί πως μια ένωση, το σφαιρικό OBG3, μειώνει τη λήψη του βάρους στα ζώα. Αυτή η ένωση είναι αποτελεσματική για την μείωση της σωματικής μάζας και για την θεραπεία νόσων και διαταραχών που σχετίζονται με την παχυσαρκία. Αυτές οι νόσοι και οι διαταραχές που σχετίζονται με την παχυσαρκία περιλαμβάνουν την υπερλιπιδαιμία, την αθηροσκλήρωση, τον διαβήτη και την υπέρταση.
CY20081101219T 2000-01-14 2008-10-27 Σφαιρικη κεφαλη του obg3 και χρησεις αυτου για την μειωση της σωματικης μαζας CY1108461T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17622800P 2000-01-14 2000-01-14
US19808700P 2000-04-13 2000-04-13
US22988100P 2000-09-01 2000-09-01
EP01942383A EP1248849B1 (en) 2000-01-14 2001-01-10 Obg3 globular head and uses thereof for decreasing body mass

Publications (1)

Publication Number Publication Date
CY1108461T1 true CY1108461T1 (el) 2014-04-09

Family

ID=27390648

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101219T CY1108461T1 (el) 2000-01-14 2008-10-27 Σφαιρικη κεφαλη του obg3 και χρησεις αυτου για την μειωση της σωματικης μαζας

Country Status (14)

Country Link
EP (1) EP1248849B1 (el)
JP (1) JP4698914B2 (el)
AT (1) ATE405655T1 (el)
AU (1) AU785090B2 (el)
BR (1) BR0107626A (el)
CA (1) CA2383136C (el)
CY (1) CY1108461T1 (el)
DE (1) DE60135439D1 (el)
DK (1) DK1248849T3 (el)
ES (1) ES2312450T3 (el)
IL (2) IL150554A0 (el)
MX (1) MXPA02006834A (el)
PT (1) PT1248849E (el)
WO (1) WO2001051645A1 (el)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405193B2 (en) 2000-05-31 2008-07-29 Serono Genetics Institute S.A. Use of Acrp30 globular head to promote increases in muscle mass and muscle differentiation
WO2003009862A1 (en) * 2001-07-20 2003-02-06 Genset S.A. Agonists and antagonists of modumet for use in the treatment of metabolic disorders
WO2003009864A1 (en) * 2001-07-23 2003-02-06 Genset S.A. Agonists and antagonists of disomet for the treatment of metabolic disorders
WO2003009861A1 (en) * 2001-07-24 2003-02-06 Genset S.A. Agonists and antagonists of metabolix in the treatment of metabolic disorders
WO2003009865A1 (en) * 2001-07-25 2003-02-06 Genset S.A. Agonists and antagonists of energen for use in the treatment of metabolic disorders
WO2003009863A1 (en) * 2001-07-26 2003-02-06 Genset S.A. Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders
WO2003011325A1 (en) * 2001-07-27 2003-02-13 Genset S.A. Agonists and antagonists of moceptin for the treatment of metabolic disorders
WO2003011323A1 (en) * 2001-07-30 2003-02-13 Genset S.A. Agonists and antagonists of contabix for use in the treatment of metabolic disorders
WO2003011324A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
WO2003011321A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of cobesin for the treatment of metabolic disorders
WO2003011318A1 (en) * 2001-08-01 2003-02-13 Genset S.A. Agonists and antagonists of famoset for use in the treatment of metabolic disorders
US20070129291A1 (en) * 2001-08-01 2007-06-07 Genset S.A. Genobix agonists and antagonists for use in the treatment of metabolic disorders
WO2003011319A1 (en) * 2001-08-02 2003-02-13 Genset S.A Xobesin agonists and antagonists for the treatment of metabolic disorders
WO2003011320A1 (en) * 2001-08-02 2003-02-13 Genset S.A. Agonists and antagonists of obesingen for the treatment of metabolic disorders
WO2003011322A1 (en) * 2001-08-02 2003-02-13 Genset S.A. Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
WO2003013579A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Lypergix agonists and antagonists for use in the treatment of metabolic disorders
WO2003013580A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Tr xidatin agonists and antagonists treatment of metabolic disorders
WO2003013581A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Agonists and antagonists of genceptin for the treatment of metabolic disorders
WO2003013582A1 (en) * 2001-08-06 2003-02-20 Genset S.A. Genoxit agonists and antagonists for use in the treatment of metabolic disorders
WO2003013578A1 (en) * 2001-08-07 2003-02-20 Genset S.A. Omoxin agonists and antagonists for use in the treatment of metabolic disorders
WO2003013585A1 (en) * 2001-08-08 2003-02-20 Genset S.A. Mifaxin agonists and antagonists for use in the treatment of metabolic
WO2003013584A1 (en) * 2001-08-09 2003-02-20 Genset S.A. Xafinix agonists and antagonists for use in the treatment of metabolic disorders
AU2002339213A1 (en) * 2001-08-09 2003-02-24 Genset S.A. Migenix agonists and antagonists for use in the treatment of metabolic disorders
WO2003013583A1 (en) * 2001-08-10 2003-02-20 Genset S.A. Faxigen agonists and antagonists in the treatment of metabolic disorders
WO2003026695A1 (en) * 2001-09-21 2003-04-03 Genset S.A. Agonists and antagonists of cylixin for the treatment of metabolic disorders
AU2002339678B2 (en) * 2001-10-05 2007-10-25 Serono Genetics Institute S.A. Fragments of the human ZN-alpha2-glycoprotein and their use in methods of treatment of obesity
WO2003041730A1 (en) * 2001-11-16 2003-05-22 Genset S.A. Ditacin agonists and antagonists for use in the treatment of metabolic disorders
WO2003045421A1 (en) * 2001-11-28 2003-06-05 Genset S.A. Agonists and antagonists of ryzn for the treatment of metabolic disorders
WO2003045422A1 (en) * 2001-11-29 2003-06-05 Genset S.A. Agonists and antagonists of prolixin for the treatment of metabolic disorders
WO2003047615A1 (en) * 2001-12-05 2003-06-12 Genset S.A. Dexar agonists and antagonists for use in the treatment of metabolic disorders
AU2002339683A1 (en) * 2001-12-05 2003-06-17 Genset S.A. Agonist and antagonists of redax for the treatment of metabolic disorders
AU2002339681A1 (en) * 2001-12-12 2003-06-23 Genset S.A. Agonists and antagonists of glucomin for the treatment of metabolic disorders
WO2003049759A1 (en) * 2001-12-13 2003-06-19 Genset S.A. Agonists and antagonists of oxifan for the treatment of metabolic disorders
AU2002339682A1 (en) * 2001-12-13 2003-06-23 Genset S.A. Emergen agonists and antagonists for use in the treatment of metabolic disorders
WO2003049756A1 (en) * 2001-12-13 2003-06-19 Genset S.A. Glucomin agonists and antagonists for use in the treatment of metabolic disorders
AU2002339688A1 (en) * 2001-12-14 2003-06-30 Genset S.A. Glucoset agonists and antagonists for use in the treatment of metabolic disorders
WO2003055916A2 (en) * 2001-12-21 2003-07-10 Maxygen Aps Adiponectin fragments and conjugates
WO2003055509A1 (en) * 2001-12-26 2003-07-10 Genset S.A. Agonists and antagonists of bromix for the treatment of metabolic disorders
AU2003223070A1 (en) * 2002-05-17 2003-12-02 Serono Genetics Institute S.A. Obg3 fragments inhibiting the conversion of active obg3 into less active obg3 and other compositions for treatment of metabolic disorders
ES2350573T3 (es) 2002-05-31 2011-01-25 Merck Serono Biodevelopment Sas Cabeza globular de obg3 ensanchada, homotrimérica y sus usos.
DK1641444T3 (en) * 2003-06-02 2016-06-27 Isis Innovation Treatment of muscle fatigue
DK1648952T3 (en) 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
WO2005044183A2 (en) * 2003-10-09 2005-05-19 Trustees Of Boston University Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis
US20080139468A1 (en) * 2004-03-31 2008-06-12 Kazuhisa Maeda Method For Control of Invasion and Use of Adiponectin
CN1740195B (zh) * 2005-04-15 2012-01-04 复旦大学 一种多肽gapM1及其制备方法
EP2041166A1 (en) * 2006-06-20 2009-04-01 Laboratoires Serono SA Process for globular adiponectin production
EP2240017B1 (en) 2008-01-04 2019-03-13 Oxford University Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
EP2088156A1 (en) 2008-02-08 2009-08-12 Institut Pasteur Use of adiponectin for the diagnosis and/or treatment of presbycusis
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
WO2014071389A1 (en) 2012-11-05 2014-05-08 Veech Richard L Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869330A (en) * 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
DE69837678T2 (de) * 1997-10-29 2007-12-27 Otsuka Pharmaceutical Co., Ltd. Compositions zur inhibierung der proliferation glatter muskulatur und verfahren zur diagnose von arteriosklerose

Also Published As

Publication number Publication date
EP1248849B1 (en) 2008-08-20
ATE405655T1 (de) 2008-09-15
CA2383136A1 (en) 2001-07-19
JP2003519633A (ja) 2003-06-24
JP4698914B2 (ja) 2011-06-08
IL150554A0 (en) 2003-02-12
PT1248849E (pt) 2008-09-08
DK1248849T3 (da) 2008-12-08
AU785090B2 (en) 2006-09-14
WO2001051645A1 (en) 2001-07-19
DE60135439D1 (de) 2008-10-02
ES2312450T3 (es) 2009-03-01
BR0107626A (pt) 2002-10-15
IL150554A (en) 2009-05-04
AU5789901A (en) 2001-07-24
EP1248849A1 (en) 2002-10-16
CA2383136C (en) 2012-09-18
MXPA02006834A (es) 2005-07-01

Similar Documents

Publication Publication Date Title
CY1108461T1 (el) Σφαιρικη κεφαλη του obg3 και χρησεις αυτου για την μειωση της σωματικης μαζας
WO2002002518A3 (en) Compounds to treat alzheimer's disease
WO2002002520A8 (en) Compounds to treat alzheimer's disease
ATE419863T1 (de) Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
EA200300944A1 (ru) Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
BR0011251A (pt) Composições de a-beta peptìdeo e processos para a produção das mesmas
WO2003099195A3 (en) Immunomodulatory compounds and methods of use thereof
GB0223038D0 (en) Therapeutic compounds
WO2004054515A3 (en) Thrombopoietin mimetics
ATE311889T1 (de) Kombination aus beta-2-adrenozeptor-agonisten und aminozuckern und ihre verwendung zur behandlung von immunmodulatorischen erkrankungen
WO2001070737A3 (en) Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof
DE60234919D1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
WO2003007732A3 (en) Pet food composition for regulating body weight and preventing obesity and related disorders in pets
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
ATE409028T1 (de) Arzneien zur behandlung von nervenerkrankungen
ATE430732T1 (de) Piperidinderivate und medikamente die diese derivate als aktiven wirkstoff enthalten
NO20045138L (no) Anvendelse av et hestemelkkonsentrat torket pa en hoydispers, biologisk inert matriks
DE60224064D1 (de) Fragmente des humanen zn-alpha2-glykoproteins und deren verwendung in methoden zur behandlung der fettleibigkeit
WO2003009871A3 (en) Inhibitors of plasminogen activator inhibitor for decreasing body mass
RU2001118219A (ru) Ингибитор ангиогенеза
DE60325275D1 (de) Verwendung des menschlichen choriongonadotropins in der behandlung von endometriose-symptomen
ATE418973T1 (de) Spirocyclopropyl-amide und -säuren und ihre therapeutischen anwendungen
BR0015996A (pt) Compostos de triazinona para o tratamento de doenças causadas pela infestação de protozoários parasìticos
DE60333917D1 (de) Homotrimerer, erweiterter globulärer kopf von obg3 und verwendungen davon
BR0007491A (pt) Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções